LianBio LIAN Stock
LianBio Price Chart
LianBio LIAN Financial and Trading Overview
| LianBio stock price | 0.32 USD |
| Previous Close | 2.45 USD |
| Open | 2.43 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 3000 |
| Day's Range | 2.42 - 2.62 USD |
| 52 Week Range | 1.07 - 3.25 USD |
| Volume | 167.24K USD |
| Avg. Volume | 203.3K USD |
| Market Cap | 278.63M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.78 USD |
LIAN Valuation Measures
| Enterprise Value | 13.71M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.2222223 |
| PEG Ratio (5 yr expected) | -0.1 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.1576135 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.113 |
Trading Information
LianBio Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 7.43% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.25 USD |
| 52 Week Low | 1.07 USD |
| 50-Day Moving Average | 2.3 USD |
| 200-Day Moving Average | 1.99 USD |
LIAN Share Statistics
| Avg. Volume (3 month) | 203.3K USD |
| Avg. Daily Volume (10-Days) | 161.27K USD |
| Shares Outstanding | 107.16M |
| Float | 27.77M |
| Short Ratio | 0.29 |
| % Held by Insiders | 5.92% |
| % Held by Institutions | 76.38% |
| Shares Short | 76.87K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.069% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.45% |
| Return on Equity (ttm) | -33.35% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -121846000 USD |
| Net Income Avi to Common (ttm) | -106609000 USD |
| Diluted EPS (ttm) | -0.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 286.54M USD |
| Total Cash Per Share (mrq) | 2.67 USD |
| Total Debt (mrq) | 3.92M USD |
| Total Debt/Equity (mrq) | 1.43 USD |
| Current Ratio (mrq) | 11.419 |
| Book Value Per Share (mrq) | 2.246 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -103716000 USD |
| Levered Free Cash Flow (ttm) | -50794624 USD |
Profile of LianBio
| Country | United States |
| State | NJ |
| City | Princeton |
| Address | 103 Carnegie Center Drive |
| ZIP | 08540 |
| Phone | 609 486 2308 |
| Website | https://www.lianbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 163 |
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Q&A For LianBio Stock
What is a current LIAN stock price?
LianBio LIAN stock price today per share is 0.32 USD.
How to purchase LianBio stock?
You can buy LIAN shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for LianBio?
The stock symbol or ticker of LianBio is LIAN.
Which industry does the LianBio company belong to?
The LianBio industry is Biotechnology.
How many shares does LianBio have in circulation?
The max supply of LianBio shares is 108.06M.
What is LianBio Price to Earnings Ratio (PE Ratio)?
LianBio PE Ratio is 0.00000000 now.
What was LianBio earnings per share over the trailing 12 months (TTM)?
LianBio EPS is 0 USD over the trailing 12 months.
Which sector does the LianBio company belong to?
The LianBio sector is Healthcare.
LianBio LIAN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}